ERBB2 and breast carcinoma: There was a phase 2 trial that demonstrated that women with high risk, stage II/III, ERBB2-negative breast cancer had improvement in pathological complete response (pCR) rate when pembrolizumab was added to standard neoadjuvant chemotherapy over patients who received chemotherapy alone (7).